2025-10-01 - Analysis Report
Okay, here's a report analyzing TG Therapeutics Inc. (TGTX) based on the data you provided.

## TG Therapeutics Inc. (TGTX) Analysis

**TG Therapeutics Inc. is a biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.**

### 1. Performance vs. S&P 500 (VOO)

*   **TGTX Cumulative Return:** 92.81%
*   **VOO Cumulative Return:** 97.56%
*   **Spread:**
    *   Max: 368.7
    *   Min: -82.1
    *   Current: 201.1
    *   Relative Spread: 62.8

**Analysis:** TGTX has underperformed the S&P 500 (VOO) with a difference of -4.75% in cumulative returns. The "relative spread" of 62.8 suggests that the current level of outperformance relative to the S&P 500 is positioned in the upper-middle range of its historical fluctuation. It's not extremely high compared to its history, but still a positive spread.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD   | Alpha  | Beta  | Cap (B) |
|------------|--------|-------|--------|-------|---------|
| 2015-2017  | -5.0%  | 73.5% | -33.0% | -0.0  | 1.3     |
| 2016-2018  | -12.0% | 73.5% | -27.0% | -0.0  | 0.7     |
| 2017-2019  | 74.0%  | 74.1% | 52.0%  | 0.0   | 1.8     |
| 2018-2020  | 316.0% | 74.1% | 293.0% | 0.1   | 8.2     |
| 2019-2021  | 124.0% | 74.1% | 78.0%  | 0.3   | 3.0     |
| 2020-2022  | -71.0% | 77.8% | -71.0% | -0.0  | 1.9     |
| 2021-2023  | -284.0%| 77.8% | -285.0%| -1.1  | 2.7     |
| 2022-2024  | 56.0%  | 77.8% | 36.0%  | -1.0  | 4.8     |
| 2023-2025  | 93.0%  | 74.8% | 31.0%  | -0.1  | 5.8     |

**Analysis:**

*   **CAGR:** Highly variable, reflecting the volatile nature of the biotech sector. Periods of significant growth (e.g., 2018-2020) are followed by sharp declines (e.g., 2021-2023).
*   **MDD:** Consistently high maximum drawdowns indicate significant risk.
*   **Alpha:** Fluctuates significantly. Positive alpha suggests outperformance relative to the market, while negative alpha indicates underperformance.
*   **Beta:** Beta values close to zero or negative suggest that TGTX's price movements have been largely uncorrelated or inversely correlated with the S&P 500 during the periods analyzed.  The Beta has become strongly negative in recent years.
*   **Capitalization:** The company's market capitalization has fluctuated, reflecting the market's changing perception of its value.

### 2. Recent Price Action

*   **Current Price:** 36.41
*   **Last Market:**
    *   Price: 36.42
    *   Previous Close: 36.83
    *   Change: -1.11%
*   **5-Day Moving Average:** 35.519
*   **20-Day Moving Average:** 33.0672
*   **60-Day Moving Average:** 32.7476

**Analysis:** The current price is slightly below the last market price (36.42), showing a small recent dip (-1.11% change).  The stock is trading above all three moving averages, suggesting a short-term and medium-term uptrend.  The 5-day moving average is above the 20-day and 60-day moving averages, reinforcing this bullish signal.

### 3. Market Risk Indicators and Expected Return

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 75.49 (Overbought)
*   **PPO:** 1.2761
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (32 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-09-02)
*   **Recent (20-day) Relative Spread Change:** +7.3 (Short-term Increase)
*   **Expected Return:** 31.4% (Long-term, vs. S&P 500)

**Analysis:**

*   **MRI:** A high MRI (0.9) suggests that, based on the model, TGTX is considered a relatively safe investment at this time.
*   **RSI:** An RSI above 70 indicates that the stock is overbought and may be due for a correction.
*   **PPO:** Positive PPO value indicates that the short-term moving average is above the long-term moving average, confirming the uptrend.
*   **Hybrid Signal:** The signal recommends full investment, aligning with the high MRI, but also highlights the MRI being 0.90 which indicates the stock is "Very Safe".
*   **Recent Relative Spread Change:** The recent increase in relative spread suggests positive momentum relative to the S&P 500, but considering the negative one-day change, this momentum may be slowing.
*   **Expected Return:** A high expected return (31.4%) suggests potential for significant outperformance versus the S&P 500 in the long term if a dollar-cost averaging strategy is used. However, this should be viewed with caution, given the company's historical volatility.
*   **Change:** The recent price change of -1.11% is a small but notable dip, which could indicate a potential short-term pullback.

### 4. Recent News & Significant Events

*   **Positive Clinical Data:** News of positive 6-year data for Briumvi showing a high percentage of multiple sclerosis patients free from progression is a significant positive catalyst.
*   **Analyst Upgrade:** B. Riley raising its price target is also a positive signal.
*   **Insider Selling:** Insider selling, while not necessarily a negative, can sometimes raise concerns.
*   **Neuraxpharm Participation:** Neuraxpharm's commitment to multiple sclerosis reinforces the space and commitment to this type of drug.

**Analysis:** The recent news is overwhelmingly positive, particularly the strong clinical data for Briumvi. This could be a significant driver of future growth. The analyst upgrade further supports this view. However, the insider selling warrants monitoring.

### 4-2. Analyst Opinions

*   **Consensus:** Buy
*   **Mean Rating:** 1.75 (Buy)
*   **Opinions:** 6
*   **Target Price:**
    *   Average: 40.83
    *   High: 55.00
    *   Low: 11.00

**Analysis:** The analyst consensus is bullish, with a strong buy recommendation. The average target price suggests moderate upside potential. However, the wide range between the high and low target prices indicates significant disagreement among analysts regarding the company's future prospects.

### 5. Recent Earnings Analysis

| 날짜       | EPS  | 매출       |
|------------|------|------------|
| 2025-08-08 | 0.19 | 0.14 B$    |
| 2025-05-09 | 0.03 | 0.12 B$    |
| 2024-11-07 | 0.03 | 0.08 B$    |
| 2024-08-09 | 0.05 | 0.07 B$    |
| 2025-08-08 | 0.05 | 0.07 B$    |

**Analysis:** The most recent earnings data (2025-08-08) shows a significant increase in both EPS and revenue compared to previous quarters. This suggests strong recent performance.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter      | Revenue | Profit Margin |
|--------------|---------|---------------|
| 2025-06-30   | $0.14B  | 86.58%        |
| 2025-03-31   | $0.12B  | 87.14%        |
| 2024-12-31   | $0.11B  | 85.77%        |
| 2024-09-30   | $0.08B  | 88.86%        |
| 2024-06-30   | $0.07B  | 88.70%        |

**Capital and Profitability:**

| Quarter      | Equity  | ROE    |
|--------------|---------|--------|
| 2025-06-30   | $0.28B  | 10.20% |
| 2025-03-31   | $0.24B  | 2.13%  |
| 2024-12-31   | $0.22B  | 10.49% |
| 2024-09-30   | $0.19B  | 2.02%  |
| 2024-06-30   | $0.18B  | 3.87%  |

**Analysis:**

*   **Revenue:** Consistent growth in revenue over the past five quarters is a positive sign.
*   **Profit Margin:** Very high profit margins suggest strong pricing power or cost control.
*   **Equity:** Increasing equity indicates a strengthening balance sheet.
*   **ROE:** Fluctuating ROE, with recent improvements, suggests variability in the company's ability to generate profit from equity.

### 7. 종합 Analysis

**Summary:**

TGTX is a high-growth, high-risk biotech company with significant potential upside. Recent clinical data for Briumvi is a major positive catalyst, supported by analyst upgrades and strong recent earnings. However, the company's historical volatility, high MDD, and recent insider selling should be considered. While the model recommends a high investment the RSI indicates a potentially overbought condition so it would be prudent to invest with caution.

**Investment Recommendation:**

Based on the analysis, a cautious approach to TGTX is warranted. The positive clinical data and growth in revenues indicate it would be prudent to invest with caution. Although the model indicates a high investment is warranted.
